MapLight Therapeutics, Inc. (MPLT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT)
The heavy selling pressure might have exhausted for MapLight Therapeutics, Inc. (MPLT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down 34.8% in 4 Weeks, Here's Why MapLight Therapeutics, Inc. (MPLT) Looks Ripe for a Turnaround
MapLight Therapeutics, Inc. (MPLT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Maplight Therapeutics' Schizophrenia Drug Hits Phase II Primary Endpoint
Maplight Therapeutics NASDAQ: MPLT reported that its Phase II ZEPHYR trial of ML-007C-MA met its primary endpoint in schizophrenia, with the twice-daily regimen producing a statistically significant improvement in Positive and Negative Syndrome Scale, or PANSS, total scores versus placebo at five weeks.
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Phase II IRIS Study Results for ML-004 in Autism Spectrum Disorder Transcript
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Phase II IRIS Study Results for ML-004 in Autism Spectrum Disorder Transcript
